December 19, 2025
1 min read

FDA outlined concerns with Elevidys’ manufacturing at Catalent site, Form 483 shows

The Elevidys-related manufacturing shortfalls were described in one of two Form 483s tied to FDA inspections that came before Catalent’s layoff spree at its Maryland gene therapy manufacturing business.

Leave a Reply

Your email address will not be published.

Previous Story

Different Mental Health Conditions Share Similar Genetics, Study Says

Next Story

Nestlé expands Materna supplement line to support pregnancy and postpartum health

Previous Story

Different Mental Health Conditions Share Similar Genetics, Study Says

Next Story

Nestlé expands Materna supplement line to support pregnancy and postpartum health

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop